DIAMEDICA THERAPEUTICS INCDMAC
ASignal's systematic analysis rates DMAC as Neutral.
Reflects the latest available analysis · analyzed Oct 8, 2026
The case on DMAC
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Positive MACD crossover indicating strengthening momentum
- Price above 20-day and 50-day moving averages
- Strong liquidity position with current ratio of 6.72x
- Low debt-to-equity ratio of 0.00x
- Cash-rich balance sheet with $43.50M in cash
- RSI at 69.52, approaching overbought territory
- Negative return on equity (-114.61%) and return on assets (-64.12%)
- Zero gross, operating, and net margins
- Negative free cash flow of $-17.65M
- Forward P/E of -9.89x and negative EV/EBITDA suggest valuation challenges
- No Reddit mentions indicating low retail investor interest
See the full verdict on DMAC
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes DMAC
Most investors never get a second opinion, let alone several. ASignal runs DMAC past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.